JAK Inhibitors: A Game Changer for the Treatment of Psoriasis Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

JAK Inhibitors: A Game Changer for the Treatment of Psoriasis

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Bristol-Myers Squibb.

Gary Goldenberg, MD

Faculty

Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Understand the immune/inflammatory cascade and their role in pathophysiology of psoriasis and other dermatologic conditions
Become familiar with the current and emerging JAK inhibitor therapies
Discern the clinical relevance of and indications for the JAK inhibitors and TYK2 inhibitors for psoriasis
Understand the safety and efficacy profile of the various JAK inhibitors
Recognize the clinical advantages and limitations of different JAKs and TYK2-inhibitor therapy for patients with psoriasis and other related immune-related diseases

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners ,and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONFLICTS OF INTEREST/DISCLOSURES

Gary Goldenberg, MD

Consultant: Abbvie, Allergan, Amgen, ALMA, Almirall, Bayer, Castle Biosciences, Celgene, Dermira, Eclipse, Galderma, Genentech, GSK/Stiefel, Intraderm, ISDIN, Janssen, Leo, Menlo, Novartis, Pharaderm, Pfizer, Ranbaxy, Regeneron/Sanofi, Scibase, Suneva, TEVA, Valeant/Ortho Dermatologic, Verrica

Speakers’ Bureau or Honoraria: Abbvie, ALMA, Bayer, Celgene, Dermira, Leo, Merz, Novartis, Pharmaderm, Pfizer, Regeneron/Sanofi
Other Financial Benefit: BOD-Verrica

[fc+357]

JAK Inhibitors: A Game Changer for the Treatment of Psoriasis Online CME Activity

JAK Inhibitors: A Game Changer for the Treatment of PsoriasisThis CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference. This activity is supported by an educational grant from Bristol-Myers Squibb.

Gary Goldenberg, MD

CONFLICTS OF INTEREST/DISCLOSURES

JAK Inhibitors: A Game Changer for the Treatment of Psoriasis

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Bristol-Myers Squibb.